Interior 2_2005.qxd - Oftalmologia.ro

OFTALMOLOGIA 2 - 2005
Pacient cu aspect clinic ]i angiografic neconcludent, prezint` MNC subfoveolar` cu exuda\ie masiv` ]i
totu]i AV relativ bun`. Dup` tratament aspectul angiografic nu se modific` dar AV cre]te la 0,5.
DMVL f`r` indica\ie de tratament, cursul natural al bolii
Nume Cs I Anul nasterii 1943
AV OD 0,5 cc
AV OS 0,7 cc
Pol Anterior C transp
FOD MNC juxtafoveolar` cu DSEP foarte extins`
FOS MNC juxtafoveolar` cu DSEP foarte extins`
Din cauza DSEP extins` nu se recomand` tratament. In ]apte luni la AO DSEP s-a extins ]i AV a sc`zut
la OD la 0,4 ]i la OS la 0,1.
Concluzii
De patru ani avem la dispozi\ie metode cu care la pacien\i cu MNC reu]im s` îmbun`t`\im (33%) s`
p`str`m (33%) acuitatea vizual` ]i la restul chiar dac` scade acuitatea vizual` aceast` sc`dere este mai mic`
decât cea în cursul natural al bolii.
BIBLIOGRAFIE
1. Michael J. Elman; Stuart L. Fine - Exudative age-related macular degeneration in Retina Editor Stephen J. Ryan vol 1
pag 175. ed.1989
2.Treatment of Age-related macular degeneration with Photodynamic therapy- TAP report 1-6
3. Verteporfin in Photodynamic therapy (VIP) report 1-6
4. Michael Sickenberg; Early detection, diagnosis and management of choiroidal neovascularization in age-related macular
degeneration: The role of ophtalmologists. Ophtalmologica 2001;215:247-253
5. TAP si VIP study group: Guidelines for using Verteporfin in Photodynamic therapy to treat choroidal neovascularization
due to age-related macular degeneration and other causes. Retina- the journal of retinal and vitreous diseases, vol 22/
nr 1/ feb 2002
6. TAP and VIP reports No.2: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfirin -
Fluorescein angiographic guidelines for evaluation and treatment - Archives of ophthalmology, sept 2003.
103